Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of recombinant PCSK9 treatment on the gene expression of EO771 cells

ABSTRACT: Effect of recombinant PCSK9 treatment on the gene expression of EO771 cells

PROVIDER: PRJNA1075439 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27941074.fastq.gz	Fastqsanger.gz
	SRR27941075.fastq.gz	Fastqsanger.gz
	SRR27941076.fastq.gz	Fastqsanger.gz
	SRR27941077.fastq.gz	Fastqsanger.gz
	SRR27941078.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Effect of recombinant PCSK9 treatment on the gene expression of EO771 cells

Project description:Identifying patients at risk for metastatic relapse is a critical need in oncology. We identified a common missense germline variant in PCSK9 that associates with reduced breast cancer survival outcomes in multiple cohorts. Genetic modeling of this gain-of-function single nucleotide variant in mice revealed that it causally promoted breast cancer metastasis. Conversely, host PCSK9 deletion reduced metastatic colonization in multiple breast cancer models. Host PCSK9 promoted metastatic initiation events in lung and increased proliferative competence by targeting tumoral LRP1 receptors which repress metastasis-promoting genes. Antibody-mediated therapeutic inhibition of PCSK9 suppressed breast cancer metastasis in multiple models. This variant stratified women in a large Swedish early-stage breast cancer cohort into those with 98% versus 78% distant-metastasis-free interval at 15 years after diagnosis. Our findings reveal that a commonly inherited genetic alteration predicts breast cancer survival and governs breast cancer metastasis—uncovering a hereditary basis underlying a prevalent cause of mortality.

2024-12-09 | GSE255558 | GEO

Effect of host PCSK9 treatment on the gene expression of EO771 primary tumor

Project description:Effect of host PCSK9 treatment on the gene expression of EO771 primary tumor

| PRJNA1075437 | ENA

Effect of host PCSK9 treatment on the gene expression of EO771 primary tumor [RNAseq_KI_tumor]

Project description:Effect of host PCSK9 treatment on the gene expression of EO771 primary tumor [RNAseq_KI_tumor]

| PRJNA1144127 | ENA

Effect of host PCSK9 treatment on the gene expression of EO771 primary tumor

2024-12-09 | GSE255560 | GEO

Effect of host PCSK9 treatment on the gene expression of EO771 primary tumor [RNAseq_KI_tumor]

2024-12-09 | GSE273936 | GEO

Effect of recombinant IGLL5 treatment on gene expressing of high endothelial venules

Project description:Effect of recombinant IGLL5 treatment on gene expressing of high endothelial venules

| PRJNA1136005 | ENA

Effect of Lrp1 knockdown on the gene expression of EO771 cells

2024-12-09 | GSE255559 | GEO

Comparing the transcriptome expression differences between breast cancer cells EO771-tdT-Parental and EO771-tdT-LM2 using high-throughput sequencing.

Project description:The molecular mechanisms that regulate breast cancer cell (BCC) metastasis and proliferation within the leptomeninges (LM) are poorly understood, limiting development of effective therapies. Here we show that BCCs in mice can invade the LM by abluminal migration along blood vessels that connect vertebral/calvarial bone marrow and meninges, bypassing the blood-brain barrier. To screen for signaling pathways in EO-LM2 cells that could support their survival or proliferation in the meningeal niche, we performed RNA-seq analysis of EO771-tdT-Parental and EO771-tdT-LM2 to compare their transcriptome expression differences.

2025-04-03 | GSE263184 | GEO

RNA-seq of mouse EO771 triple-negative breast cancer model with stemness inhibitors: salinomycin, SB-431542, JIB-04, napabucasin, and their quadruple combination against an untreated control

Project description:We conducted an in vivo study of stemness inhibitors using the EO771 triple-negative breast cancer mouse model. Ten days after subcutaneous injection of 1 million of EO771 cells into 8-12 week C57BL/6 female mice right flank, tumors reached around 100-200 mm³. Each treatment group (n=2-3 per group) received three doses of stemness inhibitors (every 3 days) in monotherapy (A - salinomycin, B - SB-431542, C - JIB-04, D - napabucasin) or combination therapy (ABCD). Control mice were left untreated. Tumors were harvested one day after the last treatment and subjected to bulk RNA-seq. This study aims to identify if treatment with stemness inhibitors affected the immune tumor microenvironment in this model.

2025-03-12 | E-MTAB-14915 | biostudies-arrayexpress

Effect of Lrp1 knockdown on the gene expression of EO771 cells

Project description:Effect of Lrp1 knockdown on the gene expression of EO771 cells

| PRJNA1075438 | ENA